Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 145

Results For "CHI"

5496 News Found

Indian Pharmacopoeia 2026 debuts with 121 new monographs targeting TB, diabetes, and cancer
News | January 04, 2026

Indian Pharmacopoeia 2026 debuts with 121 new monographs targeting TB, diabetes, and cancer

Coverage has been significantly strengthened across key therapeutic categories, including anti-tubercular, anti-diabetic and anti-cancer medicines, as well as iron supplements, thereby ensuring more comprehensive standardisation of medicines used under various National Health Programmes


BioVarta 2025 puts the spotlight on translating biotech innovation into impact
News | January 04, 2026

BioVarta 2025 puts the spotlight on translating biotech innovation into impact

Leaders from science, policy, industry, and investment came together in New Delhi to examine how alignment across the biotechnology value chain can turn innovation into outcomes at scale


CORONA Remedies posts double-digit growth in Q2, H1 FY26; PAT surges up to 35%
News | January 03, 2026

CORONA Remedies posts double-digit growth in Q2, H1 FY26; PAT surges up to 35%

The company’s consolidated revenue from operations rose to Rs. 361.13 crore in Q2 FY26 and Rs. 707.67 crore for the first half


Govt. issues draft amendment to remove cough syrups from Schedule K
Policy | January 01, 2026

Govt. issues draft amendment to remove cough syrups from Schedule K

Once finalized, cough syrups will no longer be available for over-the-counter sale


Rare arm cancer defeated: Indore doctors save patient’s arm with complex surgery
News | January 01, 2026

Rare arm cancer defeated: Indore doctors save patient’s arm with complex surgery

The surgical team used LD Flap Reconstruction, a specialised technique that rebuilt elbow strength and movement


Ultragenyx’s Setrusumab falls short in Phase 3 osteogenesis imperfecta trials
Clinical Trials | January 01, 2026

Ultragenyx’s Setrusumab falls short in Phase 3 osteogenesis imperfecta trials

The trials did not show a statistically significant reduction in annualized clinical fracture rates compared to placebo or bisphosphonates


WORK Medical scores regulatory approval for AI-powered blood analyzer
Medical Device | January 01, 2026

WORK Medical scores regulatory approval for AI-powered blood analyzer

It performs white blood cell differential counts and quantifies red blood cell and platelet morphology,


StimLabs secures FDA nod for groundbreaking human umbilical cord-derived device
Medical Device | January 01, 2026

StimLabs secures FDA nod for groundbreaking human umbilical cord-derived device

Theracor is derived from human umbilical cord extracellular matrix (ECM) and is designed to cover, protect, and maintain a moist wound environment


Johnson & Johnson completes $3.05 billion acquisition of Halda Therapeutics
News | January 01, 2026

Johnson & Johnson completes $3.05 billion acquisition of Halda Therapeutics

The acquisition adds HLD-0915, a once-daily oral therapy for prostate cancer, to Johnson & Johnson’s nearly 20-year legacy of innovation in the disease


Shenzhen Biopharma leader Lu Xianping wins EY Entrepreneur Of The Year 2025 award
People | December 31, 2025

Shenzhen Biopharma leader Lu Xianping wins EY Entrepreneur Of The Year 2025 award

Under his leadership, Chidamide became China’s first original small-molecule anti-tumor innovative drug and the country’s first pharmaceutical product globally licensed out